echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Ou Tangjing(R) (Engligliflozin Tablets) new indication for adult patients with heart failure with preserved ejection fraction has submitted an application for registration in China

    Ou Tangjing(R) (Engligliflozin Tablets) new indication for adult patients with heart failure with preserved ejection fraction has submitted an application for registration in China

    • Last Update: 2021-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Shanghai, October 11, 2021/PRNewswire/ - On September 30, 2021, Boehringer Ingelheim-Eli Lilly jointly announced that it has formally submitted its Diabetes Alliance's SGLT2 to the China National Medical Products Administration Center for Drug Evaluation Inhibitor Otangjing® (generic name: Enpagliflozin tablets) is used for the registration application of new indications for adult patients with heart failure with preserved ejection fraction


    Heart failure is a set of complex clinical syndromes caused by abnormal changes in the structure and/or function of the heart caused by various reasons, which cause ventricular contraction and/or diastolic dysfunction.


    The registration application of Otangjing® for the indications of heart failure in adult patients with preserved ejection fraction is based on the EMPEROR-Preserved Phase III clinical trial.


    Dr.


    Dr.


    [i] GBD 2016 Disease and Injury Incidence and Prevalence Collaborators.


    [ii] Gurwitz JH, Magid DJ, Smith DH, Goldberg RJ, McManus DD, Allen LA, Saczynski JS, Thorp ML, Hsu G, Sung SH, Go AS.


    [iii] China-HF

    [iv] Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H; CHART-2 Investigators.


    [v] REPRESENT-HF study.


    [vi] Shah SJ, Borlaug B, Kitzman D, et al.


    [vii] Ponikowski P, Anker SD, AlHabib KF, et al.


    Source: Boehringer Ingelheim

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.